Track Palatin Technologies, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Palatin Technologies, Inc. PTN · Stock Open Palatin Technologies, Inc. in new tab

6.23 USD
P/E
91.77
EPS
-2.96
P/B
1.75
ROE
-877.53
Beta
0.32
Target Price
43.13 USD
Palatin Technologies, Inc. logo

Palatin Technologies, Inc.

🧾 Earnings Recap – Q2 2026

Palatin Pharmaceuticals reported revenue growth in Q2 FY2026, driven by collaborations, while significantly enhancing its balance sheet through a successful public offering. Net losses increased as the company invested heavily in advancing its obesity-focused drug pipeline.

  • Completed an upsized public offering raising $18.2 million, restoring compliance with NYSE listing standards.
  • Revenue for the quarter was $116,000, marking a significant increase from zero in the prior year, due primarily to collaborations.
  • Operating expenses rose to $7.4 million, attributed to increased investments in obesity programs and higher compensation costs.
  • Net loss widened to $7.3 million, reflecting the absence of prior year's sale gains and ongoing R&D expenditures.
  • Cash position improved to $14.5 million, providing sufficient runway into FY2027 to advance ongoing clinical programs.
📅
Loading chart...
Key Metrics
Earnings dateNov. 16, 2026
P/E91.77
EPS-2.96
Book Value3.76
Price to Book1.75
Debt/Equity3.35
% Insiders8.110%
Growth
Revenue Growth-0.80%
Estimates
Forward P/E-4.82
Forward EPS-1.36
Target Mean Price43.13

DCF valuation

Model fair value for Palatin Technologies, Inc. (PTN)
Result
Sign in to run the valuation for PTN.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
4 analysts · consensus Strong buy · mean target 43.13 USD (low 12.00, high 60.00) · as of 12 Nov 2026
Low 12.00
Mean 43.13
High 60.00
Price 6.23
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Palatin Technologies, Inc. Logo Palatin Technologies, Inc. Analysis (PTN)

United States Health Care Official Website Stock

Is Palatin Technologies, Inc. a good investment? Palatin Technologies, Inc. (PTN) is currently trading at 6.23 USD. Market analysts have a consensus price target of 43.13 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 91.77. This high multiple suggests investors have priced in significant future growth expectations.

Earnings Schedule: Palatin Technologies, Inc. is expected to release its next earnings report on Nov. 16, 2026. The market consensus estimate for Forward EPS is -1.36.

Investor FAQ

Does Palatin Technologies, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Palatin Technologies, Inc.?

Palatin Technologies, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Nov. 16, 2026. The company currently has a trailing EPS of -2.96.

Company Profile

Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity completed Phase 2 clinical trial; completed a phase 2 of diabetic nephropathy It also provides pl9643 for dry eye disease; and oral PL8177 for inflammatory bowel diseases. licensing arrangements and other strategic transactions to advance and maximize the value of certain product candidates and program for the treatment of retinal diseases and with Altanispac Labs for PL9643 for the treatment of dry eye disease; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Princeton, New Jersey.

Exchange Ticker
ASE (United States) PTN
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
Sept. 27, 2010 1:10
Aug. 31, 2022 1:25
Aug. 12, 2025 1:50
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion